Validation of the Dutch TAPS-tool for substance use screening
Implementation and Validation of the Dutch Translation of the TAPS-tool: a Screener for Tobacco, Alcohol, Prescription Medication and Other Substances for Patients With Severe Mental Illness With and Without Intellectual Disability
This study is testing a new tool to see how well it can help identify substance use in patients, both with and without intellectual disabilities, who are receiving treatment for mental health issues.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Radboud University Medical Center Academic / other |
| Locations | 3 sites (Boekel, Noord Brabant and 2 other locations) |
| Trial ID | NCT05273021 on ClinicalTrials.gov |
What this trial studies
This study aims to validate the Dutch version of the TAPS-tool, which screens for substance use among patients. It will involve two groups: patients without intellectual disabilities receiving treatment from Flexible Assertive Community Treatment (FACT) teams and patients with intellectual disabilities, for whom an adjusted version of the tool will be developed. The outcomes from the TAPS-tool will be compared to a gold standard assessment to determine its reliability and validity. The study will take place in standardized care settings where patients are routinely assessed for various mental health and substance use issues.
Who should consider this trial
Good fit: Ideal candidates include patients treated in FACT teams or those with intellectual disabilities receiving care at the LVB-P department.
Not a fit: Patients who do not speak Dutch sufficiently or cannot concentrate for 20 minutes will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the screening and assessment of substance use issues in diverse patient populations, leading to better-targeted interventions.
How similar studies have performed: Other studies have shown success in validating screening tools for substance use, indicating that this approach is promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All patients treated in the participating FACT teams and for patients treated at the LVB-P (department for patients with intellectual disabilities and psychiatric disorders \[Dutch name\]) department of the GGZ Oost Brabant or the ORO foundation (ORO is no abbreviation but just a name of the institute). Exclusion Criteria: * If patients do not have sufficient command of the Dutch language or cannot concentrate for 20 minutes, the instruments are not taken
Where this trial is running
Boekel, Noord Brabant and 2 other locations
- GGZ Oost Brabant - FACT — Boekel, Noord Brabant, Netherlands (Recruiting)
- GGZ Oost Brabant - LVB-P — Boekel, Noord Brabant, Netherlands (Recruiting)
- Stichting ORO — Helmond, Noord Brabant, Netherlands (Recruiting)
Study contacts
- Study coordinator: Birgit Seelen, MSc
- Email: birgit.seelen-delang2@ru.nl
- Phone: 0031 681405847
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.